Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM
Conditions: Type 2 Diabetes Mellitus (T2DM) Interventions: Drug: Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets; Drug: Dapagliflozin tablets and Metformin HCl extended-release tablets Sponsors: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | China Health | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Forxiga | Metformin | Research